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METHOD FOR PREPARING OREGANIC 
ACID 
FIELD OF THE INVENTION 
[0001] The present invention relates to a neW process for 
the synthesis of oreganic acid and derivatives thereof, to the 
intermediate compounds of the synthesis and to the use of 
these compounds in the preparation of oreganic acid and their 
derivatives . 
STATE OF THE ART 
[0002] The compound (Z)-3,4-dicarboxy-20-sulfooxy-3 
eicosenoic acid, also knoWn as oreganic acid, of formula 1-Z 
is a natural product belonging to the family of alkyl citrates 
and having a Ras FTase inhibitory activity. The inhibition of 
the famesylation process of Ras proteins is considered as an 
effective mechanism for controlling the groWth of tumors 
promoted by mutated Ras proteins, since said inhibition pre 
vents mutated Ras proteins from being introduced in the cell 
membrane and being activated, not being able to carry out 
their biological activity. For a study of the biological activity 
of oreganic acid see: Silverman, K. C.; Jayasuriya, H.; Cas 
cales, C.;V“1lella, D.; Bills, G. F.; Jenkins, R. G.; Singh, S. B.; 
Lingham, R. B. Biochem. Biophis. Res. Commun. 1997, 232, 
478-481. 
[0003] Oreganic acid Was isolated by Dr. Jayasuriya’s 
group in the year 1996 from an unidenti?ed endophytic fun 
gus (MF 6046), isolated from living leaves of Berberis 
oregana (Berberidaceae) leaves in Lord Ellis Summit, Hum 
boldt Co. California, USA. For the purpose of elucidating the 
structure of oreganic acid, the trimethylated ester derivative 
and their corresponding desulfated derivative Were prepared. 
0 OMe O OMe 
OH OSO3H 
l5 15 
[0004] HoWever, When elucidating their structure, E isom 
erism Was incorrectly assigned to it (see Jayasuriya, H.; Bills, 
G. F.; Cascales, C.; Zink, D. L.; GoetZ, M. A.; Jenkins, R. G.; 
Silverman, K. C.; Lingham, R. B.; Singh, S. B. Bioorg. Med. 
Chem. Len. 1996, 6, 2081-2084) 
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l-E 
(incorrect isomerism) 
[0005] Subsequently, Dr. Gibbs’ group represented 
oreganic acid With a Z (correct) geometry in the tetrasubsti 
tuted double bond betWeen the C3 -C4 positions (Gibbs, R. A. ; 
Zahn, T. J.; Sebolt-Leopold, J. S Curr Med. Chem. 2001, 8, 
1437-1465). Nevertheless, data justifying that the con?gura 
tional assignment Was correct Were not provided. 
[0006] No total synthesis of oreganic acid has been 
described up until noW. In this context, it Would be convenient 
to provide a process for obtaining oreganic acid, Which pref 
erably meets the folloWing characteristics: 
[0007] using a small number of protecting groups; 
[0008] feasible and inexpensive commercial starting 
substrates; 
[0009] a reasonable number of steps; 
[0010] non-sophisticated experimental processes; or 
[0011] a good ?nal yield. 
BRIEF DESCRIPTION OF THE INVENTION 
[0012] The authors of the invention have prepared the ?rst 
total synthesis described to date of oreganic acid and deriva 
tives thereof. Said synthesis uses simple starting substrates, 
involves a reasonable number of steps, needs feW protecting 
groups and does not comprises complex transformations. 
Therefore, it alloWs obtaining oreganic acid With a good 
yield, and folloWing conditions Which Would enable the syn 
thesis at a large scale and in a short time. 
[0013] Therefore, a ?rst aspect of the invention relates to a 
process for obtaining a compound of formula (VIII), an inter 
mediate of oreganic acid and their derivatives, Which already 
comprises the ?nal backbone of the molecule, Which com 
prises subjecting a compound of formula (VI) or (VII) to a 
hydrogenation reaction; or deprotecting the trialkylsilyl 
group of a compound of formula @(VI). 
[0014] Additional aspects of the invention are said com 
pounds of formula (VI), (VII) and @(VI), their stereoisomers, 
or mixtures thereof, intermediates of the synthesis, and pro 
cesses for obtaining them. 
[0015] An additional aspect of the present invention relates 
to a process for obtaining compounds of formula (I), their 
stereoisomers, or mixtures thereof, from compounds of for 
mula (VI), (VII) or (XVI), their stereoisomers, or mixtures 
thereof through compounds of formula (VIII), their stereoi 
somers, or mixtures thereof. 
[0016] Additional aspects of the invention relate to com 
pounds of formula (I), (IV), (V), (VI), (VII), (VIII), (IX), 
@(V), @(VI) and @(VIII) de?ned herein. 
[0017] Another aspect of the invention corresponds to the 
use of at least one compound selected from the compounds of 
formula (II), (III), (IV), (V), (VI), (VII), (VIII), Oi), Oil), 
@(II), (XIII), (XIV), @(V), (XVI), (XVIII) and @(XIV), their 
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stereoisomers, or mixtures thereof, for the synthesis of com 
pounds of formula (I), their stereoisomers, or mixtures 
thereof. 
DETAILED DESCRIPTION OF THE INVENTION 
De?nitions 
[0018] For the purpose of facilitating the understanding of 
the present invention, the meanings of several terms and 
expressions as they are used in the context of the invention are 
herein included beloW. 
[0019] “Alkyl” refers to a radical With a hydrocarbon chain 
Which consists of carbon and hydrogen atoms, Which does not 
contain unsaturations and Which is attached to the rest of the 
molecule by means of a single bond. The number of carbon 
atoms of the alkyl group is speci?ed in each case. For 
example, When “C1-C4 alkyl” is indicated, it refers to an alkyl 
group of one, tWo, three of four carbon atoms, i.e., methyl, 
ethyl, propyl, isopropyl, n-butyl, sec-butyl or tert-butyl. 
[0020] “Aryl” refers to an aromatic substituent, preferably 
C6-Cl8, more preferably C6-C14, more preferably C6-C 10, 
Which comprises a simple aromatic ring or multiple fused 
rings in Which at least one of them is aromatic. Preferred aryl 
groups are phenyl or naphthyl, preferably phenyl. 
[0021] “Halogen” means iF, 4C1, iBr or fl. 
[0022] “Trialkylsilyl” is understood as a radical of formula 
iSi(R')(R")R"', Wherein each of R', R" and R'" are indepen 
dently selected from among a phenyl group and a C l-C6 alkyl 
group. Non-limiting examples of trialkylsilyl groups can be 
trimethylsilyl, triethylsilyl, tri-iso-propylsilyl; dimethyl iso 
propylsilyl, diethylisopropylsilyl, dimethylthexylsilyl, tert 
butyldimethylsilyl, tert-butyldiphenylsilyl. 
[0023] “Bn” means benZyl (i(CH2)-phenyl). 
[0024] “Leaving group” is an atom or group of atoms acti 
vating the carbon to Which they are attached against a nucleo 
philic reagent, such that said nucleophile, or part of said 
nucleophile, is attached to the molecule and the leaving group 
is detached therefrom. Leaving groups are knoWn by the 
person skilled in the art, for example, OTs (tosyl), OMs 
(mesyl) or halogen. 
[0025] The references of the present document to substi 
tuted groups in the compounds of the present invention refer 
to the speci?ed moiety Which canbe substituted in one, tWo or 
three available positions With one, tWo, three suitable groups, 
Which are independently selected from the group consisting 
of cyano; alkanoyl, such as a Cl-C6 alkanoyl group, such as 
acyl and the like; carboxamido (i(C:O)NH2); trialkylsilyl. 
As a non-limiting example, “substituted alkyl” includes 
groups such as cyanoethyl, acetylmethyl, carboxamidom 
ethyl (4CH2CONH2), 2-trimethylsilylethyl. 
[0026] Throughout the present invention, When positions of 
the different compounds are mentioned, the numbering fol 
loWed is: 
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[0027] The chain attached to the carbon of position 4 Will be 
referred to as “side chain”. As Will be discussed beloW, all the 
compounds of the present invention containing a double bond 
betWeen the C3-C4 positions can have said double bond With 
a Z con?guration, With an E con?guration or can be found as 
mixtures of Z/E isomers. The present invention includes said 
stereoisomers or mixtures thereof, all of them being useful in 
the synthesis of compounds of formula (I). One of the sub 
stituents of said double bond attached by means of a “Wavy” 
bond JVVV‘ , to highlight this possibility. 
[0028] Unless otherWise indicated, the compounds of the 
invention also refer to those including compounds Which 
differ only in the presence of one or more isotopically 
enriched atoms. For example, the compounds having the 
present structures, With the exception of the substitution of a 
hydrogen With a deuterium or With tritium, or the substitution 
of a carbon With a 13 Cior l4C-enriched carbon, are Within 
the scope of this invention. 
[0029] The reaction products obtained can be puri?ed, if 
desired, by means of conventional methods, such as crystal 
liZation, chromatography and trituration. 
Synthesis 
[0030] According to a ?rst aspect, the present invention 
relates to a process for obtaining a compound of formula 
(VIII), its stereoisomers or mixtures thereof 
(VIII) 
0 O 
O i/ \R3 
R2 \0 I 
0 
R1/ n OH 
0 
wherein 
, an are 1n e en ent se ecte rom 0031 R1 R2 dR3 'dp d 1y 1 df 
substituted or unsubstituted C l-C2O alkyl; and 
[0032] n is an integer betWeen 2 and 20; 
characterized in that it comprises at least one of the folloWing 
steps (a), (b) or (c) 
[0033] (a) subjecting a compound of formula (VI), its ste 
reoisomers or mixtures thereof, to a hydrogenation reac 
tion 
(VI) 
O O 
O i/ \R3 
R2 \0 I 
Rl/O l — m2 OBn 
O 
Wherein 
[0034] R1, R2 and R3 are as de?ned above; 
[0035] m1 is an integer Which is selected from 1, 2, 3, 4 
and 5; and 
[0036] m2 is an integer betWeen 0 and 13; 
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[0037] (b) subjecting a compound of formula (VII), its ste 
reoisomers or mixtures thereof, to a hydrogenation reac 
tion 
(v11) 
OBn 
Wherein 
[0038] n, R1, R2 and R3 are as de?ned above; 
or 
[0039] (c) removing the trialkylsilyl group of a compound 
of formula @(VI), its stereoisomers or mixtures thereof 
(XVI) 
Wherein 
[0040] n, R1, R2 and R3 are as de?ned above; and 
R4 is a trialkylsilyl group. 
[0041] In a preferred embodiment, a metal catalyst is added 
on a solution of a trimester of formula (VI) or (VII) in a 
suitable solvent, such as 1,4-dioxane for example. Preferably, 
the solvent is degassed by means of passing a stream of an 
inert gas. The suspension thus prepared is stirred under a 
hydrogen atmosphere for a time betWeen 10 and 210 minutes, 
preferably betWeen 20 and 150 minutes, more preferably 
betWeen 25 and 80 minutes. 
[0042] The conditions under Which heterogeneous hydro 
genation reactions are performed are knoWn for the person 
skilled in the art. For a revieW on heterogeneous hydrogena 
tion reactions see, for example: Nishimura, S. Heterogenous 
Catalytic Hydrogenation for Organic Synthesis; John Wiley 
& Sons, 2001 . Various metal catalysts are used, in Which the 
metal is selected from platinum, palladium, rhodium or ruthe 
nium. Some commercial catalysts of the hydrogenation reac 
tion useful for the purposes of the present invention are, for 
example, Ni(Ra), Pd/C, Rh(Al2O3). Among them, the pre 
ferred catalyst is Pd/ C. 
[0043] As can be seen, in the case of the compounds of 
formula (VI), it is thus possible to reduce the double bond of 
the side chain rather than the conjugated double bond existing 
betWeen the C3-C4 carbons, and release the end hydroxyl 
group of the side chain. In the case of the compounds of 
formula (VII) it is enough to release the end hydroxyl of the 
side chain. Alternatively, it is possible to only reduce the 
double bond of the side chain to a compound of formula (VI) 
to obtain a compound of formula (VII), Which can be reduced 
Dec. 8, 2011 
in the same reaction medium or after isolation, to a compound 
of formula (VIII). In other Words, the reduction of the com 
pounds of formula (VI) to the compounds of formula (VIII) 
can be performed in a single step, or in tWo steps through a 
compound of formula (VII). 
[0044] For example, conditions under Which the compound 
of formula (VI) is relatively diluted in the reaction medium 
(0.02-1.5 M), preferably 0.07-1.5 M, and Pd/C ofa concen 
tration betWeen 3 and 7%, preferably 5%, favor directly 
obtaining an alcohol of formula (VIII) as a single product. 
Preferred embodiments for directly obtaining compounds of 
formula (VIII) are also those Wherein betWeen 0.01-0.1 
equivalents, preferably 0.04-0.06 equivalents, of Pd/C are 
added. According to another preferred embodiment, the sol 
vent is 1,4-dioxane. The reaction time is preferably betWeen 
50 and 70 minutes. 
[0045] Preferred conditions for obtaining a compound of 
formula (VII) from compounds of formula (VI) are those in 
Which the concentration of the compound of formula (VI) in 
the reaction medium and the concentration of Pd/ C is slightly 
higher. Thus, for example, according to a preferred embodi 
ment the concentration of the compound of formula (VI) in 
the reaction medium is greater than 0.15 M, preferably of 
0.16-0.25 M), more preferably about 0.2M, and Pd/C of a 
concentration betWeen 8 and 12%, preferably 10%, is used. 
Preferred embodiments for obtaining compounds of formula 
(VII) are also those Wherein betWeen 0.01-0.1 equivalents, 
preferably 0.04-0.06 equivalents, of Pd/C are added. Accord 
ing to another preferred embodiment, the solvent is 1,4-diox 
ane. The reaction time is preferably betWeen 10 and 50 min 
utes, preferably betWeen 20 and 40 minutes, more preferably 
about 30 minutes. 
[0046] As can be observed, option (c) comprises the 
removal of the trialkylsilyl group, i.e., the transformation of 
R4 into a hydrogen, of a compound of formula @(VI). Said 
transformation is normally understood as a deprotection and 
can be performed under different conditions (see for example, 
Kocienski, P. J. Protecting Groups; Thieme: Stuttgart, 2000. 
pp.: 187-230). According to a preferred embodiment, the 
trialkylsilyl group is removed from a compound of formula 
@(VI) to give rise to a compound of formula (VIII) in diluted 
acidic medium, such as 1% HCl, for example 
[0047] According to another aspect, the invention relates to 
compounds of (VI), (VII), or @(VI) as de?ned above, imme 
diate precursors of the compounds of formula (VIII). Accord 
ing to a preferred embodiment, in the compounds of formula 
(VII) or @(VI) n is an integer betWeen 8 and 20, preferably 
betWeen 12 and 17, more preferably betWeen 13 and 16, more 
preferably n is 15. According to a preferred embodiment, in 
the compounds of formula (VI) m1 is an integer Which is 
selected from 2, 3 or 4, preferably m1 is 3. According to a 
preferred embodiment, m2 is an integer Which is selected 
from among 5-12, preferably 8-12, more preferably m2 is 10. 
[0048] Said groups R1, R2 and R3 act as protecting groups 
for the acid groups of the compounds of formula (I) and, as 
seen beloW, they are removed in the last steps of the synthesis. 
Therefore, any substituted or unsubstituted C l-C2O alkyl pro 
tecting group, orthogonal to the rest of the protecting groups 
used in the synthesis (for example, benZyl and trialkylsilyl) is 
useful for the purposes of the present invention. Preferably, 
each of R1, R2 and R3 is independently selected from a C 1 -C4, 
preferably C1_3, alkyl group more preferably, R1, R2 and R3 
are methyl groups. 
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[0049] Another aspect of the present invention relates to a 
process for the synthesis of a compound of formula (V I). Said 
compound of formula (VI), its stereoisomers or mixtures 
thereof, can be prepared by reacting a compound of formula 
(V) With a phosphonate of formula (XIII) in the presence of a 
base: 
(V) 
O 
R2 o \O 
O _ 
Rl/ ml m2 OBn 
0 
(X111) 
0 0 
RO\ / 0R3 
Wherein 
[0050] R1 is selected from a substituted or unsubstituted 
Cl-C2O alkyl; and 
[0051] R is selected from Cl-C4 alkyl substituted or 
unsubstituted With one or more halogen atoms, benZyl, 
phenyl and tolyl. 
[0052] Reactions of this type are known in the state of the 
art and alloW a certain variability in their conditions (for 
example, see Wittig see: Maryanoff, B. E.; ReiZt, A. B. Chem. 
Rev. 1989, 89, 863-927). The phosphonate is preferably in an 
excess With respect to the compound of formula (V), more 
preferably in a proportion betWeen 1.5 to 3 equivalents, still 
more preferably in a proportion of 2.2 equivalents. As has 
been mentioned, this transformation furthermore needs the 
presence of a base, such as lithium bases for example, such as 
n-BuLi, t-BuLi, s-BuLi, LDA, LiHMDS for example; sodium 
bases, such as NaH, NaHMDS for example; or potassium 
bases, such as KHMDS, t-BuOK for example. The base is 
preferably NaH. The amount of base depends on the amount 
of phosphonate used. Thus, the base is preferably in an excess 
With respect to the compound of formula (V), more preferably 
in a proportion betWeen 1 .5 -3. In a preferred embodiment, the 
reaction is performed using THF at room temperature as a 
solvent. 
[0053] Depending on the reaction conditions and the spe 
ci?c substituents, the reaction leads to mixtures of the C3-C4 
geometric isomers of the compound (VI) in a different ratio. 
Both isomers are Within the scope of the present invention and 
alloW the synthesis of oreganic acid and its derivatives, as 
discussed beloW. 
[0054] A compound of formula (V) can be prepared by 
reacting a compound of formula (TV) With an oxalate of 
formula C(11) in the presence of a base: 
(x11) 
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-continued 
(1V) 
R1/O ml — m2 OBn 
O 
Wherein 
[0055] R1 and R2 are independently selected from a sub 
stituted or unsubstituted C l-C2O alkyl; 
[0056] m1 is an integer Which is selected from 0, 1, 2, 3, 
4 and 5; and 
[0057] m2 is an integer betWeen 0 and 13. 
[0058] As has been mentioned, this transformation further 
more needs the presence of a base, such as lithium bases for 
example, such as n-BuLi, t-BuLi, s-BuLi, LDA, LiHMDS for 
example; sodium bases, such as NaH, NaHMDS for example; 
or potassium bases, such as KHMDS, t-BuOK for example. 
The base is preferably NaH. 
[0059] According to a preferred embodiment, the reaction 
is suitably performed in a mixture of MeOH/THF, using a 
temperature of about 70° C. 
[0060] A compound of formula (TV) can be prepared by 
reacting a compound (111) With a compound of formula (XI): 
9 (9 (X1) XAIQWOBH 
(III) 
O 
R1 / ml \ 0 
wherein 
[0061] R1 is selected from a substituted or unsubstituted 
C l-C2O alkyl, 
[0062] m1 is an integer Which is selected from 0, 1, 2, 3, 
4 and 5; 
[0063] m2 is an integer betWeen 0 and 13; 
[0064] X is a halogen; and 
[0065] each of the Ar groups is independently selected 
from among the C6-C 1O aryl groups. 
[0066] Experimentally, the treatment of a compound of 
formula Gil) With a base leads to the formation of the corre 
sponding ylide, Which reacts With the compound of formula 
(III) to obtain a compound of formula (IV). 
[0067] Preferably, the base used is n-BuLi, the aryl is phe 
nyl and the halogen is Br. 
[0068] It is therefore possible to prepare a compound of 
formula (V l) by means of the folloWing synthetic sequence: 
[0069] (i) reacting a compound of formula (111) With a com 
pound of formula Gil) to yield a compound of formula (IV) 
[0070] (ii) reacting said compound of formula (TV) With an 
oxalate of formula C(11) in the presence of a base to yield 
a compound of formula (V); and 
[0071] (iii) reacting said compound of formula (V) With a 
phosphonate of formula (XIII). 
[0072] The process for the synthesis of a compound of 
formula (XI) Was performed by folloWing the methodology 
described in Garcia, 1.; Lo'peZ, M.; Romeo, J. Tetrahedron: 
Asymmetry 1999, 10, 2617-2626, Which is incorporated in its 
entirety by reference. The process comprises the folloWing 
steps 
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[0073] (i) reacting a benZylating agent in the presence of a 
base With a compound of formula @(XI) 
(PO41) 
HOMOH 
Wherein 
[0074] m2 is an integer betWeen 0 and 13; 
to obtain a compound of formula (XXII) 
(XXII) 
HOMOBH 
[0075] (ii) reacting said compound of formula @(XII) With 
a halogenating agent to obtain a compound of formula 
(294V) 
XWOBH 
Wherein 
[0076] m2 is an integer betWeen 0 and 13; and 
[0077] X is a halogen atom; 
and 
[0078] (iii) reacting said compound of formula @(XV) in 
the presence of a triarylphosphorus of formula PAr3 to 
obtain said compound of formula @(I). 
[0079] According to a particular embodiment, the com 
pound of formula @(XI) is 1,12-dodecanediol. Preferably, the 
deprotonation of the latter With a base, such as NaH for 
example, folloWed by treatment With a benZylating agent, 
such as BnBr for example, leads to 12-benZyloxy-1-dode 
canol (6). Then, in the compound (6), the alcohol is substi 
tuted With a halogen. The halogen is preferably bromine. This 
bromination reaction can be carried out in the presence of 
PPh3 and CBr4. 
[0080] The halogenated compound of formula (X) is pref 
erably transformed into a compound of formula (XI) by treat 
ment With triphenylpho sphine. 
[0081] The compounds of formula (III) can be prepared by 
means of the oxidation of alcohols of formula (IIa) 
R10 
Won 
0 
(Ila) 
Wherein 
[0082] R1 is selected from a substituted or unsubstituted 
Cl-C2O alkyl; and 
[0083] ml is an integer Which is selected from 0, 1, 2, 3, 
4 and 5; 
[0084] OxidiZing agents for the transformation of alcohols 
into aldehydes are knoWn by the person skilled in the art 
(Larock, R. C. Comprehensive Organic transformations; 
John Wiley & Sons: NeW York, 1999, pp.: 1234-1249). 
According to a preferred embodiment, said oxidiZing agent is 
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selected from the group consisting of PCC (pyridinium chlo 
rochromate), MnO2, and DMSO/(COCl)2/Et3N, preferably 
PCC. 
[0085] Said compounds of formula (IIa) can be prepared 
from compounds of formula (XXIVa) 
0E0) ml
Wherein 
[0086] m1 is an integer Which is selected from 0, 1, 2, 3, 
4 and 5; 
according to the process described in Bosone, E.; Farina, P.; 
GuaZZi, G.; Innocenti, S.; Marotta, V. Synthesis 1983, 942 
944, in the presence of an alcohol of formula RlOH, wherein 
R1 has the meaning indicated above. 
[0087] According to a particular embodiment, the treat 
ment of e-caprolactone (compound of formula (XXIVa) 
Wherein m1 is 3) in acidic medium using as a solvent an 
alcohol of formula RlOH, preferably wherein R1 is a Cl-C3 
alkyl, more preferably methanol, leads to the formation of the 
corresponding compound of formula (IIa), Wherein the sub 
stituent Rl corresponds to the rest of the alcohol used as a 
solvent. This alcohol of formula (IIa) gives rise to the corre 
sponding compound of formula (III) by means of an oxida 
tion reaction. The oxidiZing reagent is preferably PCC. 
[0088] Alternatively, the side chain of a compound of for 
mula (VIII) can be elongated to provide a compound of for 
mula (VIII) With a longer chain. According to a preferred 
embodiment, in the process of the invention the compound of 
formula (VIII), its stereoisomers or mixtures thereof, is a 
compound of formula (VIIIa), its stereoisomers or mixtures 
thereof, 
(VIIIa) 
Wherein 
[0089] R1, R2 and R3 are independently selected from 
substituted or unsubstituted C1-C20 alkyl; and 
[0090] 
it additionally comprises the folloWing steps 
[0091] (i) activating as a leaving group the hydroxyl group 
of a compound of formula (VIIIa), its stereoisomers or 
mixtures thereof, to form a compound of formula @(VIII), 
its stereoisomers or mixtures thereof 
m3 is an integer betWeen 2 and 18; 
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O O (xvIII) 
o \ R3 
R2 \O 
O 
Rl/ m3 Y 
0 
wherein 
[0092] m3, R1, R2 and R3 are as de?ned above; and 
[0093] Y is selected from iOSO3H, OMs, iOTs, I and 
Br; 
[0094] (ii) reacting said compound of formula @(VIII), its 
stereoisomers or mixtures thereof, With a compound of 
formula (X) 
(X) 
MMOBII 
Wherein 
[0095] M is a metal; and 
[0096] m4 is an integer betWeen 0 and 18; and 
[0097] the relation m3+m4+2:n is met; 
to obtain a compound of formula (VII), its stereoisomers or 
mixtures thereof 
(VII) 
\0 I 
0 
R1/ n OBn 
0 
wherein 
[0098] n, R1, R2 and R3 are as de?ned above, 
and 
[0099] (iii) subjecting said compound of formula (VII), its 
stereoisomers or mixtures thereof, to a hydrogenation reac 
tion. 
[0100] In the context of the present invention, preferred 
leaving groups are those Which are active against organome 
tallic reagents (nucleophilic groups) used in the formation of 
carbon-carbon bonds, preferably Grignard reagents trans 
metalated or non-transmetalated With Zn, Al, or Cu. Preferred 
leaving groups are iOTs, fl, iBr, Cl, iSO3H. In a pre 
ferred embodiment, the leaving group is selected from Br and 
OTs. 
[0101] In a preferred embodiment, the hydroxyl group is 
activated as the corresponding tosylate (OTs) in the presence 
of a base, such as pyridine for example. 
[0102] According to another preferred embodiment, the 
treatment of a compound of formula (VIII) With CBr4 and 
PPh3 gives rise to the compound of formula (XVIII) Wherein 
Y is Br. 
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[0103] The compounds of formula (XVI) can be prepared 
by reacting a compound of formula (XV) With a phosphonate 
of formula (XIII) in the presence of a base 
0 O (xIII) 
RO\ / 0R3 
0 (XV) 
R2 o \o 
0 
R1/ .1 0R4 
0 
Wherein 
[0104] R is selected from Cl-C4 alkyl substituted or 
unsubstituted With one or more halogen atoms, benZyl, 
phenyl and tolyl; and 
[0105] R3 is selected from a substituted or unsubstituted 
Cl-C2O alkyl; and 
[0106] n, R1, R2 and R4 are as de?ned above. 
[0107] The reactions of the compounds of formula (V) or 
@(V) With the phosphonates of formula (XIII) can give rise to 
mixtures of Z(cis)/E(trans)-isomers Which can be separated, 
subjected to the folloWing step as a mixture or enriched in the 
Z(cis)-isomer according to the process described beloW. 
[0108] The compounds of formula @(V) can in turn be 
obtained by reacting an oxalate of formula @(II) With a com 
pound of formula (XIV) 
(xII) 
o 
R2 o \o 
o—R2 
(XIV) 
o 
Rl/ Wort“ 
0 
wherein 
[0109] R2 is selected from a substituted or unsubstituted 
Cl-C2O alkyl; and 
[011 0] 
[0111] As can be seen, the process folloWed for the synthe 
sis of the compounds of formula @(IV) and (XV) is similar to 
the one used to synthesiZe the compounds of formula (V) and 
(VI), and the conditions can be the same or similar. 
[0112] According to a particular embodiment, a compound 
of formula @(IV) is prepared by means of the treatment of an 
alcohol of formula (II) With a base and a silylating agent 
n, R1 and R4 are as de?ned above. 
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(11) 
R10 
WOH 
O 
wherein 
[0113] R1 and n are as de?ned above. 
[0114] Non-limiting examples of conditions under Which 
this transformation for protecting the hydroxyl group can be 
carried out can be found in, for example, Dalla, V.; Catteau, J. 
P. Tetrahedron 1999, 55, 6497-6510, and the trialkylsilyl 
groups Which can be used in this reaction, as Well as reagents 
suitable for their introduction and removal, are knoWn for the 
person skilled in the art (for example see Greene, T. W.; Wuts, 
P. G. M. Greene’s Protective Groups in Organic Synthesis; 
John Wiley & Sons: Hoboken, 2007. 
[0115] According to a particular embodiment, the base 
used is imidaZole and the silylating agent is TBDMSCl. 
[0116] According to another particular embodiment, the 
compounds of formula (II) can be prepared by reacting a 
compound of formula (XXIV) in the presence of an alcohol of 
formula RlOH, wherein R1 and n are as de?ned above 
(xxrv) 
[0117] As can be seen, the process folloWed for the synthe 
sis of the compounds of formula (II) is similar to the one used 
to synthesize the compounds of formula (IIa), and the condi 
tions can be the same or similar. 
[0118] An additional aspect of the present invention relates 
to a process for the synthesis of a compound of formula (I), 
(I) 
O OH 
O i/ 
HO 
HO 
n oso3n 
[0119] Wherein n is an integer betWeen 2 and 20; 
its stereoisomers or mixtures thereof, characterized in that it 
comprises at least one of the folloWing steps (ai), (aii) or (aiii) 
[0120] (ai) subjecting a compound of formula (VI), its ste 
reoisomers or mixtures thereof, to a hydrogenation 
o o 
0 j/ \R3 
R2 
Rl ml m2 OBn 
(VI) 
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[0121] (aii) subjecting a compound of formula (VII), its 
stereoisomers or mixtures thereof, to a hydrogenation 
(v11) 
or 
[0122] (aiii) removing the trialkylsilyl group of a com 
pound of formula (XVI), its stereoisomers or mixtures 
thereof 
(XVI) 
Wherein 
[0123] n is an integer betWeen 2 and 20; 
[0124] R1, R2 and R3 are independently selected from a 
substituted or unsubstituted C l-C2O alkyl; 
[0125] m1 is an integer Which is selected from 0, 1, 2, 3, 
4 and 5; 
[0126] m2 is an integer betWeen 0 and 13; and 
[0127] R4 is a trialkylsilyl group; 
to obtain a compound of formula (VIII), its stereoisomers or 
mixtures thereof 
(VIII) 
Wherein 
[0128] n, R1, R2 and R3 are as de?ned above; 
and additionally comprises 
[0129] (b) reacting said compound of formula (VIII), its 
stereoisomers or mixtures thereof, With a sulfating agent to 
yield a compound of formula (IX), its stereoisomers or 
mixtures thereof 
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(IX) 
wherein 
[0130] n, R1, R2 and R3 are as de?ned above; 
and 
[0131] (c) hydrolyZing the ester groups of said compound 
of formula (IX), its stereoisomers or mixtures thereof, to 
provide the corresponding acid groups. 
[0132] Various sulfating agents are knoWn for the person 
skilled in the art. The most common are SO3 and HSO3Cl. 
The sulfating agent is preferably the SO3.pyridine complex. 
[0133] The hydrolysis of ester groups to provide the corre 
sponding acid groups is knoWn by the person skilled in the art 
(see for example, Kocienski, P. J. Protecting Groups; Thieme: 
Stuttgart, 2000. pp.: 393-425). In this case, they Would be 
conditions inert to the C3 -C4 double bond and to the sulfate 
group present in the compounds of formula (IX). Non-limit 
ing conditions for the purposes of the present invention are 
preferably those in Which the hydrolysis of the compounds of 
formula (IX) is performed in the presence of an alkali metal or 
alkaline earth hydroxide, for example in the presence of 
LiOH, NaOH, Ba(OH)2, or in the presence of NaZS. 
[0134] As has been indicated above, both C3-C4 stereoiso 
mers of the compounds described in the present invention, as 
Well as the mixture thereof are included Within the present 
invention. 
Z 
O OH 
O 
HO 
HO 
O 
E 
HO O 
O 
OH 
HO 
O 
[0135] For example, the reduction of a compound of for 
mula (VI)-Z leads to products With a Z con?guration and the 
reduction of a compound of formula (VI)-E leads to products 
With a Z con?guration. 
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[0136] HoWever, it is possible to transform the E(trans) 
isomer into the Z (cis) isomer into the corresponding Z(cis) 
isomer or enrich a mixture of Z(cis)/E(trans)-isomers in the 
Z(cis)-isomer by means of exposure to a basic medium. 
Therefore, according to a preferred embodiment the process 
of the invention comprises obtaining a compound of formula 
cis-(I), cis-(VI), cis-(VII), cis-(VIII), cis-(VIIIa), cis-(IX), 
cis-QiVI), cis-(XVIa) or cis-(XVIII) or the enrichment in the 
cis-isomer of a mixture of cis- and trans-isomers of a com 
pound of formula (I), (VI), (VII), (VIII), (VIIIa), (IX), @(VI), 
@(VIa) or (XVIII), by means of the exposure to a basic 
medium of a compound of formula trans-(I), trans-(VI), 
trans-(VII), trans-(VIII), trans-(VIIIa), trans-(IX), trans 
QiVI), trans-(XVIa) or trans-@(VIII), or a mixture of cis- and 
trans-isomers of a compound of formula (I), (VI), (VII), 
(VIII), (VIIIa), (IX), (XVI), (XVIa) or @(VIII). According to 
a preferred embodiment, the process of the invention com 
prises transforming a compound of formula trans-(VI), trans 
(V II), trans-(IX) and/or trans-@(VI) into the corresponding 
compound of formula trans-(V I), trans-(V II), trans-(IX) and/ 
or trans-@(VI), or in mixtures of the corresponding cis/trans 
isomers. Said basic medium preferably comprises SO3.pyri 
dine. 
Compounds 
[0137] As has already been indicated above, additional 
aspects of the present invention are compounds of formula 
(IV), (V), (VI), (VII), @(V), @(VI) and (XVIII), their stere 
oisomers or mixtures thereof, as de?ned above. 
[0138] Another additional aspect is a compound of formula 
(VIII), its stereoisomers or mixtures thereof, as de?ned above 
With the exception of a compound of formula 
O OMe 
MeO 
MeO 
15 OH. 
[0139] Another additional aspect is a compound of formula 
(I), its stereoisomers or mixtures thereof, as de?ned above, 
except 
HO 
H0 
15 OSO3H. 
[0140] Another additional aspect is a compound of formula 
(IX), its stereoisomers or mixtures thereof, as de?ned above, 
except 
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O OMe 
MeO 
MeO 
15 OSO3H. 
Compounds of Formula (V111b) 
[0141] An additional aspect of the present invention is 
aimed at a process for preparing a compound of formula 
(V111b), Which comprises reacting a compound of formula 
(XXX) With a hydride, preferably NaBH4 (see Burke, S. D.; 
Danheiser, R. L. Handbook of Reagents for Organic Synthe 
sis: Oxidizing and Reducing Agents; John Wiley & Sons: 
Chichester, 1999. pp.: 394-400). 
(VIHb) 
0 0R3 
0 
R10 on 
R20 
r11 
0 
(W) 
R2020 O 
R1020 \ l 
R3O2C 
Wherein 
[0142] R1, R2 and R3 are independently selected from 
substituted or unsubstituted C l-C2O alkyl; and 
[0143] n1 is an integer betWeen 1 and 16, preferably 
betWeen 3 and 12, more preferably betWeen 5 and 10, 
more preferably 8; 
[0144] According to a preferred embodiment, said com 
pound of formula @(XX) is prepared by reacting a compound 
of formula (XXX1) With a compound of formula (XXX11) in 
the presence of a compound of formula PAr3, preferably 
triphenylphosphine, Wherein each of the Ar groups is inde 
pendently selected from a C6-C 1O aryl group, and Wherein n, 
R1, R2 and R3 are as de?ned above. To see a non-limiting 
example of conditions for preparing compounds of formula 
(XXX), seeYavari, 1.; SamZadeh-Kermani,A. R. Tetrahedron 
Lett. 1998, 39, 6343-6344. 
(W1) 
OH 0 
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-continued 
/ 
[0145] According to another preferred embodiment, said 
compound of formula (XXX1) is prepared by reacting a com 
pound of formula (XXX111) With an oxalate of formula (X11) 
in the presence of a base, Wherein n1 and R2 are as de?ned 
above. 
1 (xxxn) 
002R 
(xxxrn) 
o 
M 
(x11) 
0 
R2 o \o 
[0146] The compounds of formula @(XXI) can be obtained 
under the conditions described in Seki, K.; 1segaWa, 1.; 
Fukuda, M.; Ohki, M. Chem. Pharm. Bull. 1984, 32, 1568 
1577; or Ashton, W. T.; Doss, G. A. J. Heterocycl. Chem. 
1993, 30, 307-31 1, Which are incorporated in their entirety by 
reference. 
[0147] In short, this process alloWs obtaining the deriva 
tives of the oreganic acid of formula (V 111b) from commercial 
starting materials (compounds of formula (XXX111) and 
C(11)) in a feW steps and With a high yield. 
EXAMPLES 
Materials and Methods 
[0148] All the reactions Were performed under an argon 
atmosphere, except those indicated in each case. The reagents 
and solvents used are from the companies Aldrich, Fluka, 
Merck, Sigma, Acros, Lancaster, SDS or Scharlau, and Were 
puri?ed by usual processes [Armarego, W. L.; Perrin, D. D. 
Puri?cation of Laboratory Chemicals; ButterWorth-Heine 
mann: Oxford, 1996] When necessary. 
[0149] The solvents used Were distilled and dried under an 
argon atmosphere. The dioxane Was degassed by passing a 
stream of argon before being used. 
[0150] The puri?cation of the reaction products Was per 
formed by column chromatography under pressure (?ash 
chromatography), using 60 Merck silica gel (With a 230-400 
mesh particle siZe) as a stationary phase and previously dis 
tilled solvents as a mobile phase. The eluent used is indicated 
in each case and the ratios of the mixture of solvents used are 
alWays volume/volume. 
[0151] The reactions Were monitored by thin layer chroma 
tography (TLC), using 60 F254 silica gel chromatography 
plates marketed by Merck. The plates Were developed using 
iodine vapors, 2% solution of 2,4-dinitrophenylhydraZine in 
EtOH (With 0.04% by volume of 97% H2804), 10% solution 
of phosphomolybdic acid in EtOH and UV light vieWer (254 
and 366 nm). 
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[0152] The general process used to create the H2 atmo 
sphere necessary for carrying out the hydrogenation reactions 
consisted of: after performing a vacuum in the reaction ?ask, 
a stream of H2 Was connected. The vacuum/H2 process Was 
repeated tWice, and ?nally tWo balloons ?lled With H2 Were 
connected. 
[0153] The reactions under high pressure conditions Were 
carried out in Kimble brand glass vials. 
[0154] The (fully decoupled) 1H and 13 C nuclear magnetic 
resonance spectra Were performed at room temperature in the 
solvent indicated in each case (CDCl3 and CD3OD) using the 
folloWing apparatuses: Varian Gemini-200 (200 MHZ), 
Varian lNOVA-300 (300 MHZ), Bruker Avance-300 (300 
MHZ) and Varian [NOVA-400 (400 MHZ). The values of the 
chemical shifts are expressed in parts per million (6, ppm), 
using as an internal reference the residual signal of the sol 
vent: CDCl3, 7.26 ppm (lH-NMR) and 77.0 ppm (13C 
NMR); CD3OD, 3.31 ppm (lH-NMR) and 49.0 ppm (13C 
NMR). 
[0155] The melting points (m.p.) Were measured in a 
Reichert brand Ko?er microscope. 
[0156] The infrared (IR) spectra Were recorded in the Per 
kin-Elmer spectrophotometer models 681 and FT-IR Spec 
trum One, and the frequencies (V) of the absorption maxima 
are expressed in cm“. The samples Were analyZed as ?lms 
betWeen NaCl crystals or in KBr discs. 
[0157] The loW resolution mass spectra (LRMS) Were 
recorded: (1) by direct injection of the sample into a HeWlett 
Packard 5973 MSD spectrophotometer using the electron 
impact (El) ioniZation technique With an ioniZation energy of 
70 eV; or (2) in a HeWlett Packard LCMS 1100 MSD spec 
trophotometer (an HPLC-coupled quadrupole analyZer) 
using the electrospray chemical ioniZation technique (APl 
ES) in positive or negative modes, applying a capillary volt 
age of 4000 V, a drying temperature of 330° C. and using a 
[1:1] HZO/MeOH mixture With 1% AcOH as a carrier. The 
data obtained are expressed in mass units (m/Z) and the values 
in parenthesis correspond to the relative intensities With 
respect to the base peak (100%). The molecular peak is speci 
?ed as M". 
[0158] The elemental analyses (E.A.) Were performed With 
the Perkin-Elmer 240C and Heraus CHN4O-Rapid analyZ 
ers. The data calculated and observed are expressed in per 
centages. 
Example 1 
Preparation of methyl 6-hydroxyhexanoate (4) 
[0159] 
[0160] A solution of e-caprolactone (25 g, 220 mmoles) in 
MeOH (25 ml) Was added to a solution of 97% H2SO4 (2.5 
ml) in MeOH (25 ml). The mixture Was heated under re?ux 
for 30 minutes. After that time, the mixture Was neutraliZed 
With an aqueous solution of 10% NaOH (17.5 ml) and 
extracted WithAcOEt (3><25 ml). The organic phase Was dried 
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With anhydrous Na2 S04, ?ltered and the solvent Was removed 
under reduced pressure, obtaining (32 g, quantitative yield) 
methyl 6-hydroxyhexanoate (4), Which Was used in the fol 
loWing step Without purifying. 
[0161] 1H-NMR (200 MHZ, CDCl3). 6 3.55 (3H, s, 
ADCH3), 3.53 (2H, t, 1:62 HZ, H-6), 2.22 (2H, t, J:7.2 HZ, 
H-2), 1.62-1.23 (6H, m, %H2i). 
Example 2 
Preparation of methyl 5-formylpentanoate (5) 
[0162] 
O / OH PCC 
cH2c12, RT 
0 
O 
/ W0 
0 
[0163] PCC (2.65 g, 12.3 mmoles) Was added to a solution 
of methyl 6-hydroxyhexanoate (4) (1.2 g, 8.19 mmoles) in 
CH2Cl2 (50 ml). The mixture Was stirred at room temperature 
for 2.5 hours. After that time, the solvent Was removed under 
reduced pressure. The residue Was suspended in a 1 :1 hexane/ 
AcOEt mixture (30 ml) and ?ltered through silica gel to 
remove the remains of the reagent, obtaining (1.16 g, quan 
titative yield) methyl 5-formylpentanoate (5), Which Was 
used in the folloWing step Without purifying. 
[0164] 1H-NMR (200 MHZ, CDCl3). 6 9.71 (1H, m, H-6), 
3.61 (3H, s, ADCH3), 2.39 (4H, m, H-2, H-5), 1.65 (4H, m, 
H-3, H-4). 
Example 3 
Preparation of 12-benZyloxy-1-dodecanol (6) 
[01 65] 
HOMOH NaH, BnBr 
THF/DMF, 0° C. 
HOMO 
[0166] A solution of 1,12-dodecanediol (5.0 g, 24.7 
mmoles) in a 2:1 THF/DMF mixture (36 ml) Was added to a 
suspension ofNaH (0.595 g, 24.83 mmoles) in DMF (18 ml) 
at 0° C. The mixture Was stirred at 0° C. for 2 hours. After that 
time, BnBr (4.42 g, 25.8 mmoles) Was added at 0° C. The 
resulting mixture Was stirred at room temperature for 4 hours. 
Then, the mixture Was cooled at 0° C. and H20 (75 ml) Was 
added. The phases Were separated, and the aqueous phase Was 
extracted With Et2O (5x20 ml). The organic phase Was 
Washed With sat. NaCl (30 ml), dried With anhydrous MgSO4, 
?ltered and the solvent Was removed under reduced pressure. 
The product Was puri?ed by a chromatographic column (hex 
ane/AcOEt, 10:1), obtaining (3.59 g, yield 50%) 12-benZy 
loxy-1-dodecanol (6), as a transparent oil. 
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[0167] lH-NMR (200 MHZ, CDC13). 0 7.36-7.27 (5H, m, 
AriH), 4.51 (2H, s, wcnzph), 3.60 (2H, 1, 1:65 HZ), 3.45 
(2H, 1, 1:64 HZ), 1.60 (4H, m), 1.40 (16H, m). 
Example 4 
Preparation of 12-benZyloxy-1-bromododecane (7) 
[0168] 
HOMO PPh3, 01314 
0112012, 0° c. 
6 
BrMO 
7 
[0169] CBr4 (3.34 g, 10.08 mmoles) Was addedto a solution 
of 12-benZyloxy-1-dodecanol (6) (2.36 g, 8.06 mmoles) and 
PPh3 (2.64 g, 10.08 mmoles) in CH2Cl2 (40 ml) at 0° C. The 
mixture Was stirred at room temperature for 30 minutes. After 
that time, the solvent Was removed under reduced pressure. 
The residue Was suspended in hexane (115 ml) and stirred at 
room temperature for 30 minutes. After that time, the mixture 
Was ?ltered under vacuum and the solvent Was removed under 
reduced pressure. The product Was puri?ed by a chromato 
graphic column (hexane/CH2Cl2, 2:1), obtaining (2.45 g, 
yield 86%) 12-benZyloxy-1-bromododecane (7), as a trans 
parent oil. 
[0170] 1H-NMR (200 MHZ, CDCl3). 6 7.35 (5H, m, 
AriH), 4.48 (2H, s, ADCH2Ph), 3.45 (2H, t, J:6.5 HZ), 3.35 
(2H, t, J:6.5 HZ), 1.85 (2H, m, iCHZi), 1.58 (2H, m, 
iCHzi), 1.36-1.15 (16H, m, %H2i). 
Example 5 
Preparation of [12-benZyloxydodec-1-yl]triph 
enylphosphonium bromide (8) 
[0171] 
BL/WO PPh3 
—> 
1200 C. 
7 
9 GM BrPh3P 10 O 
8 
[0172] A mixture of 12-benZyloxy-1-bromododecane (7) 
(1.58 g, 4.44 mmoles) and PPh3 (1.28 g, 4.89 mmoles) Was 
heated in a Kimble at 120° C. for 3 hours. After that time, the 
product Was puri?ed by a chromatographic column (CH2Cl2/ 
MeOH, 9:1), obtaining (2.5 g, yield 91%) [12-benZyloxy 
dodec-1-yl]triphenylphosphonium bromide (8), as a trans 
parent oil. 
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[0173] lH-NMR (200 MHZ, CDC13). 0 7.70 (15H, m), 7.22 
(5H, m, A1411), 4.52 (2H, s, iOCHZPh), 3.80 (2H, m, 11-1), 
3.38 (211,1, 1:65 HZ, 11-12), 1.55 (4H, m, 1.36-1.15 (16H, m, 
%H2i). 
Example 6 
Preparation of methyl 6-(tert-butyldimethylsilyloxy) 
hexanoate (24) 
[0174] 
O TBDMSCI, irnidazole 
/ OH —>
DMF, RT 
O 
O 
/ WOTBDMS 
o 
24 
[0175] A solution ofTBDMSCl (7.16 g, 46.08 mmoles) in 
DMF (10 ml) Was added to a solution of methyl 6-hydroxy 
hexanoate (4) (5.613 g, 38.40 mmoles) and imidaZole (3.13 g, 
46.08 mmoles) in DMF (50 ml) at 0° C. The mixture Was 
stirred at room temperature for 24 hours. After that time, H20 
(80 ml) and AcOEt (40 ml) Were added. The phases Were 
separated, and the aqueous phase Was extracted With AcOEt 
(3x20 ml). The organic phase Was Washed With sat. CuSO4 
(2x30 ml) and sat. NaCl (2x30 ml), dried With anhydrous 
Na2SO4, ?ltered and the solvent Was removed under reduced 
pressure. The product Was puri?ed by a chromatographic 
column (hexane/AcOEt, 25:1), obtaining (6.46 g, yield 73%) 
methyl 6-(tert-butyldimethylsilyloxy)hexanoate (24) as a 
colorless oil. 
[0176] 1H-NMR (200 MHZ, CDCl3). 6 3.56 (3H, s, 
ADCH3), 3.49 (3H, t, 1:62 HZ, H-6), 2.21 (2H, t, J:7.6 HZ, 
H-2), 1.61-1.20 (6H, m, iCHZi), 0.78 (9H, s, tert-BuSi), 
—0.06 (6H, s, (Me)2Si). 
Example 7 
Preparation of methyl rac-(R)-7-(tert-butyldimethyl 
silyloxy)-3-(methoxycarbonyl)-2-oxoheptanoate (25) 
[0177] 
O 
O 
NaH, \o \ 
O O 
/ \H/WOTBDMS —> THF, MeOH, 0° C. 
O 
24 
O 
O \O 
O 
/ OTBDMS 
O 
25 
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[0178] MeOH (0.23 ml) Was added to a suspension of NaH 
(0.507 g, 21.11 mmoles) in THF (9.2 ml) at 0° C. The mixture 
Was stirred until it reached room temperature. Then, dimethyl 
oxalate (2.29 g, 19.19 mmoles) and methyl 6-(tert-butyldim 
ethylsilyloxy)hexanoate (24) (5.0 g, 19.19 mmoles) Were 
added. The resulting mixture Was heated under re?ux for 3 
hours. After that time, H20 (10 ml) and an aqueous solution of 
10% HCl Were added until neutral pH. The phases Were 
separated, and the aqueous phase Was extracted With AcOEt 
(3><10 ml). The organic phase Was dried With anhydrous 
Na2SO4, ?ltered and the solvent Was removed under reduced 
pressure. The product Was puri?ed by a chromatographic 
column (hexane/AcOEt, 25:1), obtaining (4.41 g, yield 67%) 
methyl rac-(R)-7-(tert-butyldimethylsilyloxy)-3-(methoxy 
carbonyl)-2-oxoheptanoate (25), as a transparent oil. 
[0179] 1H-NMR (200 MHZ, CDCl3). 6 3.92 (1H, t, 1:68 
HZ, H-3), 3.78 (3H, s, iOCH3), 3.62 (3H, s, ADCH3), 3.49 
(2H, t, 1:59 HZ, H-7), 1.87-1.41 (6H, m, %H2i), 0.77 
(9H, s, tert-BuSi), —0.07 (6H, s, (Me)2Si). 
Example 8 
Reaction of methyl rac-(R)-7-(tert-butyldimethylsily 
loxy)-3-(methoxycarbonyl)-2-oxoheptanoate (25) 
With methyl(dimethoxypho sphoryl)acetate 
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butyldimethylsilyloxy)-3-(methoxycarbonyl)-2-oxohep 
tanoate (25) (0.100 g, 0.29 mmoles) in THF (0.3 ml) Was 
added. The resulting mixture Was stirred at room temperature 
for 24 hours. After that time, Celite Was added and the solvent 
Was removed under reduced pressure. The product Was puri 
?ed by a chromatographic column (hexane/AcOEt, 15:1), 
obtaining (0.063 g, yield 54%) methyl(Z)-8-(tert-butyldim 
ethylsilyloxy)-3,4-bis(methoxycarbonyl)-3-octenoate 
(26-Z) and (0.024 g, yield 21%) methyl(E)-8-(tert-butyldim 
ethylsilyloxy)-3,4-bis(methoxycarbonyl)-3-octenoate 
(26-E), both as a transparent oil. 
Methyl(Z)-8-(tert-butyldimethylsilyloxy) -3 ,4-bis 
(methoxycarbonyl)-3-octenoate (26-Z) 
[0182] 
O O 26-Z 
O \ 
\O 
O 
/ OTBMDS 
O 
[0183] lH-NMR (200 MHZ, CDC13). 6 3.67 (3H, s, 
wcm), 3.62 (3H, s, 40cm), 3.57 (3H, s, wcm), 3.48 
(2H, m, H-8), 3.29 (2H, s, H-2), 2.26 (2H, m, H-5), 1.40 (4H, 
m, icnzi), 0.76 (9H, s, tert-BuSi), -0.08 (6H, s, (Me)2Si). 
Methyl(E)-8-(tert-butyldimethylsilyloxy) -3 ,4-bis 
(methoxycarbonyl)-3-octenoate (26-E) 
[0184] 
26-E 
[0180] 
NaH, 
0 
\ O O 
O (OM6)2OP O/ 
/O OTBDMS THF, RT 
0 
25 
O O 
O \ 
\O 
O 
/ OTBDMS 
O 
26-Z 
+ 
26-E 
[0181] A solution of methyl(dimethoxyphosphoryl)acetate 
(0.105 g, 0.57 mmoles) in THF (0.3 ml) Was added to a 
suspension of NaH (0.013 g, 0.57 mmoles) in THF (2.3 ml). 
The mixture Was stirred at room temperature until H 2 Was no 
longer evolved. Then, a solution of methyl rac-(R)-7-(tert 
[0185] 
ADCH3), 3.57 (3H, s, iOCH3), 3.49 (2H, m, H-8), 3.41 
(2H, s, H-2), 2.53 (2H, m, H-5), 1.41 (4H, m, %H2i), 0.77 
(9H, s, tert-BuSi), —0.07 (6H, s, (Me)2Si). 
lH-NMR (200 MHZ, CDC13). 6 3.67 (6H, s, 
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Example 9 
Preparation of methyl(Z)-8-hydroxy-3,4-bis(meth 
oxycarbonyl)-3-octenoate (27-Z) 
[0186] 
O o o\ 
\0 1% HCl 
0 MeOH 
/ OTBDMS 
o 
26-Z 
o o 
O \ 
\o 
o 
/ OH 
0 
27-Z 
[0187] A solution of methyl(Z)-8-(tert-butyldimethylsily 
loxy)-3,4-bis(methoxycarbonyl)-3-octenoate (26-Z) (0.100 
g, 0.24 mmoles) in HCl (1% in MeOH, 1 ml) Was stirred at 
room temperature for 2 hours . After that time, the mixture Was 
neutralized With an aqueous solution of 10% NaHCO3 (1 ml), 
and CH2Cl2 (2 ml) Was added. The phases Were separated, 
and the aqueous phase Was extracted With CH2Cl2 (3 x2 ml). 
The organic phase Was Washed With sat. NaCl (2 ml), dried 
With anhydrous Na2SO4, ?ltered and the solvent Was removed 
under reduced pressure, obtaining (0.065 g, yield 95%) 
methyl(Z)-8-hydroxy-3,4-bis(methoxycarbonyl)-3 
octenoate (27-Z) as a colorless oil. 
[0188] 1H-NMR (200 MHZ, CDCl3). 6 3.79 (3H, s, 
iOCH3), 3.73 (3H, s, ADCH3), 3.69 (3H, s, iOCH3), 3.63 
(2H, t, 1:60 HZ, H-8), 3.42 (2H, s, H-2), 2.40 (2H, t, J:7.4 
HZ, H-5), 1.58 (4H, m, iCHZi). 
Example 10 
Preparation of methyl(Z)-3,4-bis(methoxycarbonyl) 
8-sulfooxy-3-octenoate (31-Z) 
[0189] 
o o 
\O SO3°PYT 
T’ O pyr1 me 
/ OH 
0 
27-2 
13 
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[0190] SO3.pyr (0.276 g, 1.73 mmoles) Was added in small 
portions to a solution of methyl(Z)-8-hydroxy-3,4-bis(meth 
oxycarbonyl)-3-octenoate (27-Z) (0.100 g, 0.34 mmoles) in 
pyridine (6.5 ml). The mixture Was stirred at room tempera 
ture for 24 hours. After that time, the solvent Was removed 
under reduced pressure. The residue Was suspended in a 1:1 
HZO/MeOH mixture (2 ml), neutraliZed With an aqueous 
solution of 0.5M KOH and the solvent Was removed under 
reduced pressure. The product Was puri?ed by trituration With 
MeOH, obtaining (0.126 g, quantitative yield) methyl(Z)-3, 
4-bis(methoxycarbonyl)-8-sulfooxy-3 -octenoate (31-Z), as a 
White solid. 
[0191] IR (BrK): v3457, 3075, 2955, 1726, 1638, 1489, 
1437, 1261, 1201, 1008, 756, 683 cm“. 
[0192] 1H-NMR (200 MHZ, CDCl3). 6 4.11 (2H, t, 1:60 
HZ, H-8), 3.78 (3H, s, ADCH3), 3.73 (3H, s, ADCH3), 3.69 
(3H, s, ADCH3), 3.42 (2H, s, H-2), 2.40 (2H, t, J:7.4 HZ, 
H-5), 1.60 (4H, m, %H2i). 
Example 11 
Preparation of methyl(Z)-3,4-bis(methoxycarbonyl) 
8-(p-toluenesulfonyl)-3-octenoate (32-Z) 
[0193] 
O O 
O \ 
\ 
O T501 
0 pyridine, RT 
/ OH 
O 
27-Z 
O O 
O \ 
\O 
O 
/ OTs 
O 
32-Z 
[0194] A solution of methyl(Z)-8-hydroxy-3,4-bis(meth 
oxycarbonyl)-3-octenoate (27-Z) (0.100 g, 0.347 mmoles) in 
pyridine (1 ml) Was added to a solution of TsCl (0.099 g, 0.52 
mmoles) in pyridine (1 ml) at 00 C. The mixture Was stirred at 
00 C. for 2 hours. After that time, H20 (4 ml) Was added. The 
US 2011/0301370 A1 
phases Were separated, and the aqueous phase Was extracted 
With Et2O (3><4 ml). The organic phase Was Washed With an 
aqueous solution of 10% HCl (><2, until an acidic pH), With 
H20 (4 ml), With sat. NaHCO3 (4 ml) and With sat. NaCl (4 
ml), dried With anhydrous MgSO4, ?ltered and the solvent 
Was removed under reduced pressure, obtaining (0.110 g, 
yield 72%) methyl(Z)-3,4-bis(methoxycarbonyl)-8-(p-tolu 
enesulfonyl)-3-octenoate (32-Z), as a colorless oil. 
[0195] 1H-NMR (200 MHZ, CDCl3). 6 7.79 (2H, d, 1:83 
HZ,AI‘*H), 7.36 (2H, d, 1:83 HZ,AI‘*H), 4.02 (2H, t, J:6.1 
HZ, H-8), 3.79 (3H, s, iOCH3), 3.75 (3H, s, ADCH3), 3.71 
(3H, s, ADCH3), 3.39 (2H, s, H-2), 2.47 (3H, s, %H3), 2.36 
(2H, t, 1:76 HZ, H-5), 1.80-1.45 (4H, m, %H2i). 
Example 12 
Preparation of methyl(Z)-8-bromo-3,4-bis(methoxy 
carbonyl)-3-octenoate (29-Z) 
[0196] 
O O 
O \ 
\O CBr4,PPh3 
—> 
O CHZCIZ, RT 
/ OH 
O 
27-Z 
O O 
O \ 
\O 
O 
/ Br 
0 
29-Z 
[0197] A solution of PPh3 (0.341 g, 1.30 mmoles) in 
CH2Cl2 (2 ml) Was added to a solution of methyl(Z)-8-hy 
droxy-3,4-bis(methoxycarbonyl)-3-octenoate (27-Z) (0.300 
g, 1.04 mmoles) and CBr4 (0.431 g, 1.30 mmoles) in CH2Cl2 
(6.5 ml) at 0° C. The mixture Was stirred at room temperature 
for 2 hours. After that time, Celite Was added and the solvent 
Was removed under reduced pressure. The product Was puri 
?ed by a chromatographic column (hexane/AcOEt, 4:1), 
obtaining (0.218 g, yield 60%) methyl(Z)-8-bromo-3,4-bis 
(methoxycarbonyl)-3-octenoate (29-Z), as a colorless oil. 
[0198] 1H-NMR (200 MHZ, CDCl3). 6 3.80 (3H, s, 
iOCH3), 3.74 (3H, s, ADCH3), 3.70 (3H, s, iOCH3), 3.42 
(2H, s, H-2), 3.39 (2H, t, 1:66 HZ, H-8), 2.39 (2H, t, J:7.9 
HZ, H-5), 1.88 (2H, m, iCHZi), 1.62 (2H, m, iCHZi). 
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Example 13 
Preparation of methyl(Z)-18-benZyloxy-6-octade 
cenoate (13) 
[0199] 
/O\"/\§42/\%O 
n-BuLi, O 
9 @ 
BrPh3P 10 0 5 
—> /\© THF, 0° c. 
8 
O _ 
/ W0 
0 
13 
[0200] n-BuLi (0.545 g, 8.52 mmoles) Was added to a solu 
tion of [12-benZyloxydodec-1 -yl]triphenylpho sphonium 
bromide (8) (3.71 g, 6.0 mmoles) in THF (85 ml) at 0° C. The 
mixture Was stirred at 0° C. for 45 minutes. After that time, a 
solution of methyl 5-formylpentanoate (5) (0.952 g, 8.34 
mmoles) in THF (2 ml) Was added at 0° C. The mixture Was 
stirred at room temperature for 1 hour. After that time, the 
reaction mixture Was cooled at 0° C. and sat. NH4Cl Was 
added (30 ml). The phases Were separated, and the aqueous 
phase Was extracted With Et2O (4x15 ml). The organic phase 
Was dried With anhydrous MgSO4, ?ltered and the solvent 
Was removed under reduced pressure. The product Was puri 
?ed by a chromatographic column (hexane/AcOEt, 20:1), 
obtaining (2.61 g, yield 53%) methyl(Z)-18-benZyloxy-6 
octadecenoate (13), as a transparent oil. 
[0201] IR (NaCl): v3004, 2926, 2854, 1741, 1496, 1454, 
1435,1362, 1204, 1170, 1102, 1028, 734, 697 cm“. 
[0202] 1H-NMR (300 MHZ, CDCl3). 6 7.30 (5H, m, 
AriH), 5.39 (1H, dt, J:7.0, 10.9 HZ, H-6 or H-7), 5.30 (1H, 
dt, 1:83, 10.9 HZ, H-7 or H-6), 4.50 (2H, s, CH2Ph), 3.66 
(3H, s, iOCH3), 3.46 (2H, t, 1:65 HZ, H-18), 2.31 (2H, t, 
1:75 HZ, H-2), 1.96 (4H, m, H-5, H-8), 1.63 (4H, m, 
4CH2i), 1.34 (18H, m, 
[0203] l3C-NMR (50 MHZ, CDCl3). 6 174.1, 138.6,130.9, 
130.4, 129.0, 128.2, 127.5, 127.3, 72.7, 70.4, 51.3, 33.9,29.7, 
29.6, 29.5, 29.5, 29.4, 29.2, 29.1, 29.0, 27.1, 26.7, 26.1, 24.5, 
24.3. 
[0204] LRMS(EI): m/Z 402(M+, 2), 371(1), 342(0), 311 
(14), 279(37), 261(16), 195(3), 91(100). 
[0205] EA. (C26H42O3): Found: C, 77.50, H, 10.45; Cal 
culated: C, 77.56, H, 10.51. 
Example 14 
Preparation of methyl rac-(Z,R)-19-benZyloxy-3 
(methoxycarbonyl)-2-oxo-7-nonadecenoate (22) 
[0206] 
O 
\O)‘\'(()\ O _ N H, 
/ 3 10 OBn a O 
THF, MeOH, 0° C. 
O 
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[0207] MeOH (0.022 ml) Was added to a suspension of 
NaH (0.044 g, 1.87 mmoles) in THF (1 ml) at 00 C. The 
mixture Was stirred until it reached room temperature. Then, 
dimethyl oxalate (0.221 g, 1.87 mmoles) and methyl(Z)-18 
benZyloxy-6-octadecenoate (13) (0.685 g, 1.70 mmoles) 
Were added. The resulting mixture Was heated under re?ux 
for 4 hours. After that time, H20 (10 ml) and an aqueous 
solution of 10% HCl Were added until neutral pH. The phases 
Were separated, and the aqueous phase Was extracted With 
AcOEt (3 x7 ml). The organic phase Was dried With anhydrous 
Na2SO4, ?ltered and the solvent Was removed under reduced 
pressure. The product Was puri?ed by a chromatographic 
column (hexane/AcOEt, 15:1), obtaining (0.70 g, yield 85%) 
methyl rac - (Z,R) -1 9 -benZyloxy-3 - (methoxycarbonyl) -2 - 
oxo-7-nonadecenoate (22), as a transparent oil. 
[0208] IR (NaCl): V3454, 3005, 2926, 2853, 1735, 1657, 
1495, 1454, 1436, 1361, 1249, 1100, 815, 735, 697 cm_l. 
[0209] 1H-NMR (300 MHZ, CDCl3). 6 7.29 (5H, m, 
AriH), 5.37 (1H, dt, 1:61, 10.7 HZ, H-7 or H-8), 5.31 (1H, 
dt, 1:68, 10.7 HZ, H-8 or H-7), 4.50 (2H, s, %H2Ph), 4.03 
(1H, t, 1:68 HZ, H-3), 3.88 (3H, s, iOCH3), 3.72 (3H, s, 
iOCH3), 3.46 (2H, t, 1:65 HZ, H-19), 1.97 (6H, m, 
iCHzi), 1.65-1.23 (20H, m, %H2i). 
[0210] l3C-NMR (75MHZ, CDCl3). 6 188.5, 169.3, 160.7, 
138.6, 130.8, 130.3, 128.2, 127.4, 127.3, 72.7, 70.4, 53.7, 
53.1, 52.4, 29.6, 29.5, 29.4, 29.4, 29.3, 29.2, 29.0, 27.1, 27.0, 
26.9, 26.7, 26.6, 26.1. 
[0211] LRMS(E1): m/Z488(M+, 0), 457(0), 397(2), 347(8), 
287(30), 237(9), 91(100). 
[0212] E.A. (C29H44O6): Found: C, 71.20, H, 9.00; Calcu 
lated: C, 71.28, H, 9.08. 
Example 15 
Reaction of methyl rac-(Z,R)-19-benZyloxy-3-(meth 
oxycarbonyl)-2-oxo-7-nonadecenoate (22) With 
methyl(dimethoxypho sphoryl)acetate 
[0213] 
O 
NaH, 
\0 O o 
O _ (OMe)2OP\)]\ / 
/ 3 10 OBn — >
THF, RT 
0 
22 
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[0214] A solution of methyl(dimethoxyphosphoryl)acetate 
(1.11 g, 6.12 mmoles) in THF (3.2 ml) Was added to a sus 
pension ofNaH (0.147 g, 6.12 mmoles) inTHF (10.6 ml). The 
mixture Was stirred at room temperature until H2 Was no 
longer evolved. Then, a solution of methyl rac-(Z,R)-19 
benZyloxy-3-(methoxycarbonyl)-2-oxo-7-nonadecenoate 
(22) (1.36 g, 2.78 mmoles) in THF (3.2 ml) Was added. The 
resulting mixture Was stirred at room temperature for 24 
hours. After that time, Celite Was added and the solvent Was 
removed under reduced pressure. The product Was puri?ed by 
a chromatographic column (hexane/AcOEt, 10:1), obtaining 
(0.754 g, yield 50%) methyl(3Z,8Z)-20-benZyloxy-3,4-bis 
(methoxycarbonyl)-3,8-eicosadienoate (23-Z) and (0.261 g, 
yield 18%) methyl(3E,8Z)-20-benZyloxy-3,4-bis(methoxy 
carbonyl)-3,8-eicosadienonate (23-E), both as a transparent 
oil. 
Methyl(3Z,8Z)-20-benZyloxy-3 ,4-bis(methoxycarbo 
nyl)-3,8-eicosadienoate (23-Z) 
[0215] 
[0216] IR (NaCl): V3448, 3003, 2926, 2853, 1735, 1645, 
1495,1454,1435,1314,1268,1198,1169,1099,1027,797, 
736, 698 cm_l. 
[0217] lH-NMR (300 MHZ, CDC13). 0 7.29 (5H, m, Ar-H), 
5.39 (1H, (11, 1:66, 10.5 HZ, H-8 01‘ H-9), 5.35 (1H, (11, 1:68, 
10.5 HZ, H-9 01‘ H-8), 4.50 (2H, s, iOCHZPh), 3.79 (3H, s, 
wcm), 3.73 (3H, s, 40cm), 3.69 (3H, s, wcm), 3.46 
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(2H, t, 1:65 HZ, H-20), 3.40 (2H, s, H-2), 2.34 (2H, m, 
iCHzi), 2.02 (4H, m, iCHZi), 1.65-1.23 (20H, m, 
iCHzi). 
[0218] l3C-NMR (75MHZ, CDCl3). 6 169.7, 169.3, 166.2, 
145.6, 138.4, 130.9, 128.5, 127.9, 127.9, 127.2, 125.4, 72.5, 
70.1, 52.0, 51.8, 51.8, 33.4, 30.5, 29.5, 29.4, 29.3, 29.2, 29.2, 
29.0, 27.2, 27.0, 26.4, 25.9. 
[0219] LRMS(E1): m/Z 544(M+, 0), 512(2), 485(2), 453(2), 
389(23), 329(8), 198(45), 166(50), 91(100). 
[0220] E.A. (C32H48O7): Found: C, 70.45, H, 9.00; Calcu 
lated: C, 70.56, H, 8.88. 
Methyl(3E, 8Z) -20-benZyloxy-3 ,4-bis(methoxycarbo 
nyl)-3,8-eicosadienoate (23-E) 
[0221] 
23-E 
[0222] IR (NaCl): V3436, 3000, 2926, 2853, 1741, 1435, 
1251, 1201, 1169, 1101, 1014, 735, 697 cm“. 
[0223] 1H-NMR (300 MHZ, CDCl3). 6 7.31 (5H, m, Ar-H), 
5.37 (1H, dt, J:7.0, 10.9 HZ, H-8 or H-9), 5.33 (1H, dt, 1:83, 
10.9 HZ, H-9 or H-8), 4.50 (2H, s, ADCH2Ph), 3.78 (6H, s, 
iOCH3), 3.68 (3H, s, ADCH3), 3.51 (2H, s, H-2), 3.46 (2H, 
t, 1:65 HZ, H-20), 2.58 (2H, m, iCH2i), 2.07 (4H, m, 
iCHzi), 1.65-1.23 (20H, m, %H2i). 
[0224] l3C-NMR (75 MHZ, CDCl3). 6 170.4, 168.6, 167.4, 
146.5, 143.7,138.6, 131.0,130.6,128.7,128.5,128.1, 127.4, 
127.2,72.7,70.3, 51.9, 51.8, 51.6,36.4,29.6,29.5,29.4,29.4, 
29.3, 29.2, 29.0, 28.5, 27.1, 26.8, 26.0. 
[0225] LRMS(E1): m/Z 544(M+, 0), 512(1), 453(3), 421(8), 
389(26), 357(13), 198(21), 91(100). 
[0226] E.A. (C32H48O7): Found: C, 70.50, H, 9.05; Calcu 
lated: C, 70.56, H, 8.88. 
Example 16 
Preparation of methyl(Z)-20-hydroxy-3,4-bis(meth 
oxycarbonyl)-3-eicosadienoate (33-Z) 
[0227] 
H2, 5% we 
1,4-dioxane 
OBn 
23-cis 
16 
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[0228] Pd/C (0.042 g, 5% by Weight, 0.02 mmoles) Was 
added to a solution of methyl(3Z,8Z)-20-benZyloxy-3,4-bis 
(methoxycarbonyl)-3,8-eicosadienoate (23-Z) (0.217 g, 
0.398 mmoles) in 1,4-dioxane (4.33 ml). The mixture Was 
stirred under an argon atmosphere at room temperature for 1 
hour. After that time, the mixture Was ?ltered through Celite 
With AcOEt and the solvent Was removed under reduced 
pressure. The product Was puri?ed by a chromatographic 
column (hexane/AcOEt, 3:1), obtaining (0.149 g, yield 82%) 
methyl(Z)-20-hydroxy-3,4-bis(methoxycarbonyl)-3-eicose 
noate (33-Z), as a White solid. 
Example 17 
Preparation of methyl(Z)-3,4-bis(methoxycarbonyl) 
20-sulfooxy-3-eicosenoate (37-Z) 
[0229] 
OH pyridine 
[0230] SO3.pyr (0.181 g, 1.11 mmoles) Was added in small 
portions to a solution of methyl(Z)-20-hydroxy-3,4-bis 
(methoxycarbonyl)-3-eicosenoate (33-Z) (0.102 g, 0.22 
mmoles) in pyridine (4.2 ml). The mixture Was stirred at room 
temperature for 2 hours. After that time, the solvent Was 
removed under reduced pressure. The residue Was suspended 
in a 1:1 HZO/MeOH mixture (2 ml), neutraliZed With an 
aqueous solution of 0.5M KOH and the solvent Was removed 
under reduced pressure. The product Was puri?ed by tritura 
tion With MeOH, obtaining (0.119 g, quantitative yield) 
methyl(Z)-3,4-bis(methoxycarbonyl)-20-sulfooxy-3-eicose 
noate (37-Z), as a White solid. 
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[0231] mp: 129-1300 C. 
[0232] IR (BrK): v3452, 2923, 2852, 1733, 1643, 1436, 
1255, 1217, 1065, 1008, 773, 619, 577 cm_l. 
[0233] 1H-NMR (300 MHZ, CDCl3). 6 4.10 (2H, m, H-20), 
3.79 (3H, s, ADCH3), 3.73 (3H, s, ADCH3), 3.69 (3H, s, 
iOCH3), 3.41 (2H, s, H-2), 2.33 (4H, m, iCHZi), 1.60 
1.24 (26H, m, iCHZi). 
[0234] l3C-NMR (75 MHZ, CDCl3). 6 170.2, 169.7, 166.7, 
146.1, 125.4, 69.8, 52.3, 52.1, 33.7, 31.3, 29.9, 29.5, 29.3, 
27.5, 25.8. 
[0235] LRMS(EI): m/Z 536(M+, 0), 518(13), 486(6), 458 
(10), 426(5), 346(7), 287(6), 198(44), 166(88), 55(100). 
[0236] EA. (C25H44OlOS): Found: C, 56.00, H, 8.30; Cal 
culated: C, 55.95, H, 8.26. 
Example 18 
Reaction of methyl(E)-20-hydroxy-3,4-bis(methoxy 
carbonyl)-3-eicosenoate (33-E) With SO3.pyr 
[0237] 
SOrpyr 
pyridine OH 
37-Z 
[0238] SO3.pyr (0.181 g, 1.11 mmoles) Was added in small 
portions to a solution of methyl(E)-20-hydroxy-3,4-bis 
(methoxycarbonyl)-3-eicosenoate. (33-E) (0.102 g, 0.22 
mmoles) in pyridine (4 .2 ml). The mixture Was stirred at room 
temperature for 2 hours. After that time, the solvent Was 
removed under reduced pres sure. The residue Was suspended 
in a 1:1 HZO/MeOH mixture (2 ml), Was neutraliZed With an 
aqueous solution of 0.5M KOH and the solvent Was removed 
under reduced pressure. The product Was puri?ed by tritura 
tion With MeOH, obtaining (0.119 g, quantitative yield) a 
mixture of methyl(E)-3,4-bis(methoxycarbonyl)-20-sul 
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fooxy-3-eicosenoate (37-E) and methyl(Z)-3,4-bis(methoxy 
carbonyl)-20-sulfooxy-3-eicosenoate (37-Z) in a 2:3 ratio, 
respectively, as a White solid. 
[0239] 1H-NMR (300 MHZ, CDCl3). 6 4.10 (2H, m, H-20 
37-Z), 3.97 (2H, m, H-20 37-E), 3.79 (3H, s, ADCH3 37-Z), 
3.78 (6H, s, iOCH3 37-E), 3.73 (3H, s, iOCH3 37-Z), 3.69 
(3H, s, ADCH3 37-Z), 3.68 (3H, s, ADCH3 37-E), 3.50 (2H, 
s, H-2 37-E), 3.41 (2H, s, H-2 37-Z), 2.60 (4H, m, %H2i 
37-E), 2.33 (4H, m, iCH2i37-Z), 1.60-1.24 (26H, m, 
%H2i 37-Z, 37-E). 
[0240] LRMS(EI): m/Z 536(M+, 0), 518(13), 486(6), 458 
(10), 426(5), 346(7), 287(6), 198(44), 166(88), 55(100). 
Example 19 
Preparation of (Z)-3,4-dicarboxy-20-sulfooxy-3 
eicosenoic acid (l-Z) 
[0241] 
LiOH 
OSO3H THF, RT 
OH 
[0242] An aqueous solution of 1 M LiOH (3.3 ml) to a 
solution of methyl(Z)-3,4-bis(methoxycarbonyl)-20-sul 
fooxy-3-eicosenoate (37-Z) (0.059 g, 0.11 mmoles) in THF 
(4.7 ml) Was added. The mixture Was stirred at room tempera 
ture for 1 hour. After that time, H20 (5 ml) Was added. The 
phases Were separated. The aqueous phase Was Washed With 
AcOEt (2><5 ml), acidi?ed With an aqueous solution of 10% 
HCl and extracted With AcOEt (3><5 ml). The extraction 
organic phase Was dried With anhydrous Na2SO4, ?ltered and 
the solvent Was removed under reduced pressure, obtaining 
(0.048 g, yield 88%) (Z)-3,4-dicarboxy-20-sulfooxy-3 
eicosenoic acid (l-Z), as a White solid. 
[0243] mp: 63-65 ° C. 
[0244] IR (NaCl): v3436, 2919, 2849, 1771, 1732, 1644, 
1464, 1190, 1052 cm“. 
[0245] 1H-NMR (300 MHZ, CD3OD). 6 3.88 (2H, t, 1:65 
HZ, H-20), 3.61 (2H, s, H-2), 2.23 (2H, m, iCHZi), 1.55 
1.18 (28H, m, iCHZi). 
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Example 20 
Preparation of methyl(Z)-2-hydroxy-4-oxo-2-tride 
cenoate (84) 
o 
NaH, \OHO\ 
—O, 
[0246] 
W THF, MeOH 
O 
O 
\O / 7 
OH O 
84 
[0247] MeOH (0.5 ml) Was added to a suspension of NaH 
(0.253 g, 10.57 mmoles) in THF (5 ml) at 0° C. The mixture 
Was stirred until reaching room temperature. Then, dimethyl 
oxalate (1.14 g, 9.69 mmoles) and a solution of 2-undecanone 
(1.5 g, 8.8 mmoles) in THF (3 ml) Were added 0.32 The 
resulting mixture Was heated at 60° C. for 5 hours. After that 
time, AcOEt (10 ml) and an aqueous solution of 10% HCl (10 
ml) Were added. The phases Were separated, and the aqueous 
phase Was extracted With AcOEt (3x10 ml). The organic 
phase Was dried With anhydrous Na2SO4, ?ltered and the 
solvent Was removed under reduced pressure. The product 
Was puri?ed by a chromatographic column (hexane/AcOEt, 
100:1), obtaining (1.18 g, yield 52%) methyl(Z)-2-hydroxy 
4-oxo-2-tridecenoate (84), as a colorless oil. 
[0248] IR (NaCl): v2922, 2853, 1739, 1720, 1648, 1543, 
1437,1018 cm_l. 
[0249] 1H-NMR (300 MHZ, CDCl3). 6 6.35 (1H, s, H-3), 
3.88 (3H, s, 4OCH3), 2.46 (2H, t, J:7.1 HZ, H-5), 1.63 (2H, 
m, H-6), 1.25 (12H, broad s, iCHZi), 0.86 (3H, m, iCH3). 
[0250] l3C-NMR (75 MHZ, CDCl3). 6 203.3, 166.3, 162.6, 
101.6, 53.0, 48.8, 31.7, 29.3, 291,290, 24.8, 23.3, 20.9, 14.0. 
[0251] LRMS(E1): m/Z 256(M+, 0), 197(100), 168(1), 155 
(12), 144(12). 
[0252] E.A. (Cl4H24O4): Found: C, 65.50, H, 9.50; Calcu 
lated: C, 65.60, H, 9.44. 
Example 21 
Preparation of methyl(2Z,4Z)-3,4-bis(methoxycarbo 
nyl)-6-oxo-2,4-pentadecadienoate (86) 
[0253] 
DMAD, PPh3 
—> 
CHZCIZ, 00 c. 
18 
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[0254] A solution of DMAD (0.138 g, 0.97 mmoles) in 
CH2Cl2 (4 ml) Was added to a solution of methyl(Z)-2-hy 
droxy-4-oxo-2-tridecenoate (84) (0.250 g, 0.97 mmoles) and 
PPh3 (0.255 g, 0.97 mmoles) in CH2Cl2 (8 ml) at 0° C. The 
mixture Was stirred at room temperature for 24 hours. After 
that time, the solvent Was removed under reduced pressure. 
The crude reaction product Was dissolved in toluene (10 ml), 
and the mixture Was heated under re?ux for 6 hours. Then, the 
solvent Was removed under reduced pressure. The product 
Was puri?ed by a chromatographic column (hexane/AcOEt, 
6:1), obtaining (0.240 g, yield 64%) methyl(2Z,4Z)-3,4-bis 
(methoxycarbonyl)-6-oxo-2,4-pentadecadienoate (86), as a 
colorless oil. 
[0255] IR (NaCl): V3428, 2952, 2928, 2851, 1727, 1695, 
1436, 1254, 1029 cm“. 
[0256] 1H-NMR (300 MHZ, CDCl3). 6 6.32 (1H, s, H-5), 
6.11 (1H, s, H-2), 3.91 (3H, s, ADCH3), 3.88 (3H, s, 
ADCH3), 3.75 (3H, s, ADCH3), 2.54 (2H, t, 1:73 HZ, H-7), 
1.62 (2H, m, H-8), 1.24 (12H, broad s, %H2i), 0.86 (3H, 
t, 1:61 HZ, —CH3). 
[0257] l3C-NMR (75 MHZ, CDCl3). 6 198.3, 166.2,165.9, 
164.4, 142.8, 138.9, 129.9, 124.5, 53.1, 53.0, 52.4, 386,318, 
29.3, 29.2, 29.0, 28.8, 23.5, 22.6, 14.0. 
[0258] LRMS(E1): m/Z 382(M+, 1), 351(4), 323(90), 291 
(11), 265(3), 255(10), 227(32), 196(100). 
[0259] E.A. (C2OH3OO7): Found: C, 62.90, H, 8.00; Calcu 
lated: C, 62.81, H, 7.91. 
Example 22 
Reaction of methyl(2Z,4Z)-3,4-bis(methoxycarbo 
nyl)-6-oxo-2,4-pentadecadienoate (86) With NaBH4 
[0260] 
NaBH4 
—> 
CHZCIZ, MeOH, 00 c. 
86 
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[0261] NaBH4 (0.009 g, 0.244 mmoles) Was added to a 
solution of methyl(2Z,4Z)-3,4-bis(methoxycarbonyl)-6-oxo 
2,4-pentadecadienoate (86) (0.360 g, 0.941 mmoles) in a 5:2 
CHZClZ/MeOH mixture (21 ml) at 00 C. The mixture Was 
stirred at 00 C. for 1 hour. After that time, sat. NH4Cl (10 ml) 
Was added. The phases Were separated, and the aqueous phase 
Was extracted With CHZCl2 (2x10 ml). The organic phase Was 
dried With anhydrous Na2SO4, ?ltered and the solvent Was 
removed under reduced pressure. The product Was puri?ed by 
a chromatographic column (hexane/AcOEt, 4:1), obtaining 
(0.020 g, yield 6%) methyl rac-(Z,R)-3,4-bis(methoxycarbo 
nyl)-6-hydroxy-3-pentadecenoate (93), as a colorless oil. 
[0262] 1H-NMR (300 MHZ, CDCl3). 6 3.80 (3H, s, 
-OCH3), 3.74 (3H, s, ADCH3), 3.70 (3H, s, iOCH3), 3.66 
(1H, m, H-6), 3.46 (2H, s, H-2), 2.48 (2H, d, 1:60 HZ, H-5), 
1.64-1.43 (4H, m, %H2i), 1.25 (16H, broad s, %H2i), 
0.86 (3H, m, %H3). 
[0263] LRMS(E1): m/Z 386(M+, 0), 353(0), 320(2), 295 
(1), 265(0), 235(1), 198(91), 166(100), 139(28), 111(10). 
1. A process for obtaining a compound of formula (V 111), 
its stereoisomers or mixtures thereof 
(VIII) 
Wherein 
R1, R2 and R3 are independently selected from substi 
tuted or unsubstituted C l-C2O alkyl; and 
n is an integer betWeen 2 and 20; 
characterized in that it comprises at least one of the folloW 
ing steps (a), (b) or (c) 
(a) subjecting a compound of formula (VI), its stereoiso 
mers or mixtures thereof, to a hydrogenation reaction 
(VI) 
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Wherein 
R1, R2 and R3 are as de?ned above; 
m1 is an integer Which is selected from 1, 2, 3, 4 and 5; 
and 
m2 is an integer betWeen 0 and 13; 
(b) subjecting a compound of formula (VII), its stereoiso 
mers or mixtures thereof, to a hydrogenation reaction 
(v11) 
Wherein 
n, R1, R2 and R3 are as de?ned above; 
or 
(c) removing the trialkylsilyl group of a compound of 
formula @(Vl), its stereoisomers or mixtures thereof 
(XVI) 
O | 
0 
R1/ n 0R4 
0 
Wherein 
n, R1, R2 and R3 are as de?ned above; and 
R4 is a trialkylsilyl group. 
2. The process according to claim 1, Wherein said hydro 
genation uses Pd/C as a catalyst and 1,4-dioxane as a solvent. 
3. The process according to any claim 1, Wherein the com 
pound of formula (V 111), its stereoisomers or mixtures 
thereof, is a compound of formula (Vllla), its stereoisomers 
or mixtures thereof, 
(VIHa) 
Wherein 
R1, R2 and R3 are independently selected from substi 
tuted or unsubstituted C l-C2O alkyl; and 
m3 is an integer betWeen 2 and 18; 
Which additionally comprises the folloWing steps 
(i) activating as a leaving group the hydroxyl group of a 
compound of formula (Vllla), its stereoisomers or mix 






